





FIG. 1

FIG. 2






FIG. 3




FIG. 4E







FIG. 4D













FIG. 7






FIG. 8F




FIG. 8E







FIG. 8D








FIG. 10




FIG. 11




FIG. 12B

FIG. 12A




FIG. 13A




FIG. 13B







FIG. 13C

	GIGA-564	Ipilimumab	CD80	CD86
R70		X	X	X
K130	X	X	X	X
Y139	X	X	X	X
L141	X	X		
I143	X	X	X	X

FIG. 13D






FIG. 15A

FIG. 15C





FIG. 15B






FIG. 15D




FIG. 15E




FIG. 16A




FIG. 16B




FIG. 16C




FIG. 16D




FIG. 17A




FIG. 17B




FIG. 18A




FIG. 18B





FIG. 18C



Ipilimumab:

- Strongly blocks CTLA-4 interaction with CD80/CD86
- ↑↑↑ LN Treg proliferation
- Weaker intratumoral Treg killing

GIGA-564:

- Weakly blocks CTLA-4 interaction with CD80/CD86
- Stronger FcR signaling
- More efficient intratumoral Treg killing

FIG. 19





FIG. 20A






FIG. 20C

FIG. 20D





FIG. 20D (Cont.)






FIG. 20E




FIG. 21




FIG. 22B




FIG. 22A




FIG. 22D

FIG. 22C




FIG. 23B




FIG. 23A




FIG. 23D




FIG. 23C




FIG. 24A




FIG. 24B




FIG. 24D




FIG. 24C




FIG. 24E




FIG. 25B




FIG. 25A




FIG. 25C

FIG. 25D




FIG. 25E




FIG. 26

Fc effector function in anti-CTLA-4 is necessary for
robust anti-tumor responses




FIG. 27




FIG. 28

CTLA-4 cell-based
signaling assay




FIG. 29




FIG. 30




FIG. 31




FIG. 32




FIG. 33

FIG. 34




FIG. 34 (CONTINUED)




FIG. 34 (CONTINUED)




FIG. 35




FIG. 35 (CONTINUED)




FIG. 35 (CONTINUED)




FIG. 35 (CONTINUED)




FIG. 36A




FIG. 36B




FIG. 36C




FIG. 36D




FIG. 36E




FIG. 37





FIG. 38







FIG. 40




FIG. 40 (CONTINUED)




FIG. 41




FIG. 42A




FIG. 42B





FIG. 43A

IgG Heavy chain domain	CH1		
IMGT exon numbering	95	96	97 98
EU numbering	212	213	214 215

<u>IgG1 allotypes</u>			
IGHG1*08	D	K	R V
IGHG1*01	D	K	K V

FIG. 43B







FIG. 44A






FIG. 45




FIG. 46A

FIG. 46B




FIG. 47A




FIG. 47B




FIG. 48B




FIG. 48A




FIG. 49B




FIG. 49A




FIG. 50B

FIG. 50A




FIG. 51B

FIG. 51A




FIG. 52B

FIG. 52A




FIG. 53




FIG. 54B




FIG. 54A

93/103




FIG. 55B





FIG. 55A







FIG. 56 (cont'd)




FIG. 57






FIG. 57 (cont'd)










FIG. 58 (cont'd)








FIG. 60




FIG. 61